There are currently 240 clinical trials in Hartford, Connecticut looking for participants to engage in research studies. Trials are conducted at various facilities, including Hartford Hospital, Connecticut Children's Medical Center, Smilow Cancer Hospital Care Center at Saint Francis and Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
NCT03937635
Recruiting
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut
Conditions: Smoldering Plasma Cell Myeloma
Register for Updates
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
NCT04566328
Recruiting
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spread... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Hartford Hospital, Hartford, Connecticut +1 locations
Conditions: Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
Register for Updates
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
NCT06022939
Recruiting
This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD alone for treating patients with newly diagnosed amyloid light chain (AL) amyloidosis. Melphalan is a chemotherapy given prior to a stem cell transplant. Giving chemotherapy before a peripheral blood stem cell transplant helps kill cancer cells in the body and helps make... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/05/2024
Locations: Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut
Conditions: AL Amyloidosis
Register for Updates
Application of Virtual Reality in Post-Operative Recovery of a Pediatric Scoliosis Patient Population
NCT06101264
Recruiting
The purpose of this study is to assess the effect of virtual reality on subjective post-operative pain, total inpatient narcotic administration, and mobilization with physical therapy in pediatric patients who have undergone surgical correction for idiopathic scoliosis.
Gender:
ALL
Ages:
Between 13 years and 18 years
Trial Updated:
07/03/2024
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Adolescent Idiopathic Scoliosis
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Hartford Hospital, Hartford, Connecticut +1 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Improving Availability of Intranasal Naloxone
NCT05877118
Recruiting
While there is a lifesaving medication called naloxone that can reverse the deadly effects of opioid overdose, patients often fail to fill the prescription at the pharmacy when it is prescribed. This is particularly concerning and true in those at the highest risk of death-those who end up in the emergency department for opioid overdose. The goal of this study is to compare the impact of different overdose education on naloxone prescription fill rates in opioid users being discharged from our ho... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
06/06/2024
Locations: Hartford Hospital Emergency Department, Hartford, Connecticut +1 locations
Conditions: Opioid Overdose
Register for Updates
Tai Chi as a Novel Strategy to Increase Physical Activity Among Adults Pursuing Metabolic and Bariatric Surgery
NCT06445413
Recruiting
The goal of this clinical trial is to evaluate the feasibility and acceptability of a 10-wk hybrid Tai Chi (TC) program with in-person classes and online TC videos among 24 physically inactive adults who are seeking metabolic and bariatric surgery (MBS) in a single-arm trial. The aims are: Aim 1: Feasibility: To evaluate whether TC is feasible, defined as a mean attendance rate of ≥70% in-person TC classes attended. Aim 2: Acceptability: To evaluate whether TC is acceptable, defined as a mean... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/04/2024
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Obesity
Register for Updates
Eliminating Monitor Overuse Trial (EMO Trial)
NCT05132322
Recruiting
The purpose of this study is to identify the optimal deimplementation strategies for an overused practice: continuous pulse oximetry monitoring of children hospitalized with bronchiolitis who are not receiving supplemental oxygen.
Gender:
ALL
Ages:
2 months and above
Trial Updated:
06/03/2024
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Bronchiolitis Acute Viral
Register for Updates
OSA-18 in Children With Mild Obstructive Sleep Apnea: Can it be a Helpful Decision Making Tool?
NCT05911646
Recruiting
The concept is a novel research idea that incorporates the potential impact of patient quality of life (QOL) on decision-making for treatment of mild obstructive sleep apnea (OSA). Our hypothesis is that in children with mild OSA there is significant conflict with parental decision-making; in the absence of significant sleep apnea, there is limited research regarding comparative efficacy of various treatment options. The impact of a QOL questionnaire can be a significant deciding factor and may... Read More
Gender:
ALL
Ages:
Between 3 years and 12 years
Trial Updated:
05/30/2024
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Apnea, Obstructive Sleep, Obstructive Sleep Apnea
Register for Updates
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others
NCT01193075
Recruiting
This is an observational longitudinal study to determine the natural history and genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C). The investigators will also be determine the capability of the newly developed CMT Pediatric Scale (CMT Peds scale) and the Minimal Dataset to measure impairment and perform longitudinal measurements in patients with multiple forms of CMT over a five year window
Gender:
ALL
Ages:
All
Trial Updated:
05/09/2024
Locations: University of Connecticut/Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Charcot Marie Tooth Disease
Register for Updates
Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2
NCT01193088
Recruiting
This project includes two projects. One is looking for new genes that cause Charcot Marie Tooth disease (CMT). The other is looking for genes that do not cause CMT, but may modify the symptoms a person has.
Gender:
ALL
Ages:
All
Trial Updated:
05/09/2024
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Charcot-Marie-Tooth Disease, Type Ia (Disorder), HMSN
Register for Updates
Development of Charcot Marie Tooth Disease (CMT) Pediatric Scale for Children With CMT
NCT01203085
Recruiting
The primary goal of this project is to develop and test a Charcot Marie Tooth disease (CMT) Pediatric Scale for use in evaluation in natural history CMT study.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
05/09/2024
Locations: University of Connecticut/Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Charcot Marie Tooth Disease
Register for Updates